Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McLaughlin

Showing results (581-590 of 726) with videos related to

Pageof 73
Sort By:
Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
International Journal of Molecular Sciences|November 9, 2024
Conformational Plasticity Enhances the Brain Penetration of a Metabolically Stable, Dual-Functional Opioid-Peptide CycloAntYangmei Li, William E Cotham, Abbe Eliasof, et al.
Leukemia & Lymphoma|June 1, 1995
Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinaseS Suki, F Swan, S Tucker, et al.
Leukemia & Lymphoma|June 1, 1997
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphomaA Younes, M A Rodriguez, P McLaughlin, et al.
Cancer|May 1, 1994
Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysisW S Velasquez, P McLaughlin, L M Fuller, et al.
Irish Journal of Medical Science|January 25, 2022
Breast cancer recurrence: factors impacting occurrence and survivalDonald Courtney, Matthew G Davey, Brian M Moloney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Small noncleaved cell lymphoma in adults: superior results for stages I-III diseaseT M Lopez, F B Hagemeister, P McLaughlin, et al.
Pharmaceuticals (Basel, Switzerland)|January 28, 2026
Characterization of Novel Sigma Receptor Ligands Derived from Multicomponent Reactions as Efficacious Treatments for Neuropathic PainRyosuke Shinouchi, Bengisu Turgutalp, Rohini S Ople, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1999
Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioidsW Xie, G M Samoriski, J P McLaughlin, et al.
AIDS (London, England)|February 1, 1997
Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New EnglandR J MacGowan, R M Brackbill, D L Rugg, et al.
Pageof 73

Showing results (581-590 of 726) with videos related to

Sort By:
Pageof 73
Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
International Journal of Molecular Sciences|November 9, 2024
Conformational Plasticity Enhances the Brain Penetration of a Metabolically Stable, Dual-Functional Opioid-Peptide CycloAntYangmei Li, William E Cotham, Abbe Eliasof, et al.
Leukemia & Lymphoma|June 1, 1995
Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinaseS Suki, F Swan, S Tucker, et al.
Leukemia & Lymphoma|June 1, 1997
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphomaA Younes, M A Rodriguez, P McLaughlin, et al.
Cancer|May 1, 1994
Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysisW S Velasquez, P McLaughlin, L M Fuller, et al.
Irish Journal of Medical Science|January 25, 2022
Breast cancer recurrence: factors impacting occurrence and survivalDonald Courtney, Matthew G Davey, Brian M Moloney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Small noncleaved cell lymphoma in adults: superior results for stages I-III diseaseT M Lopez, F B Hagemeister, P McLaughlin, et al.
Pharmaceuticals (Basel, Switzerland)|January 28, 2026
Characterization of Novel Sigma Receptor Ligands Derived from Multicomponent Reactions as Efficacious Treatments for Neuropathic PainRyosuke Shinouchi, Bengisu Turgutalp, Rohini S Ople, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1999
Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioidsW Xie, G M Samoriski, J P McLaughlin, et al.
AIDS (London, England)|February 1, 1997
Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New EnglandR J MacGowan, R M Brackbill, D L Rugg, et al.
Pageof 73